News Updates
Scope

Wed, May 27, 2026

1 updates
ARWR
7:00 AM

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in

Presentation / Abstract • Phase 1/2EASL 2026 poster presentation Wed, May 27, 2026arrowheadpharma.com

Tue, May 26, 2026

1 updates
ARWR
10:00 AM

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the

Presentation / Abstract • Phase 3Oral presentation Tue, May 26, 2026, 8:30 AM EESTarrowheadpharma.com

Thu, May 7, 2026

1 updates

Tue, May 5, 2026

1 updates

Mon, May 4, 2026

1 updates
ARWR
7:30 AM

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group Dinner Date/Time: May 12, 2026

Presentation / Abstractarrowheadpharma.com

Fri, May 1, 2026

1 updates

Fri, Apr 24, 2026

1 updates
ARWR
6:39 AM

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of

arrowheadpharma.com

Mon, Apr 20, 2026

1 updates
ARWR
4:01 PM

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 20, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.

arrowheadpharma.com

Sat, Mar 28, 2026

1 updates
ARWR
10:30 AM

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis – No adjudicated acute pancreatitis events occurred in any patient

Presentation / Abstract • Phase 2arrowheadpharma.com